To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer

This is a single-arm, open-label, dose-escalating Phase 1 clinical study. It aims to evaluate the safety, tolerability and pharmacokinetic(PK) profiles of the investigational agent, and preliminarily assess its efficacy in subjects with advanced/metastatic renal cell carcinoma, and determine the recommended dose and infusion regimen for Phase 2 trials.

Trial Details

NCT ID
NCT07647744
Phase
PHASE1
Sponsor
Hrain Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Anti-Human CD70 T-Cell Injection
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age 18 to 70 years (inclusive), regardless of gender;
  • Life expectancy of more than 12 weeks;
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 1;
  • Subjects with advanced/metastatic renal cell carcinoma (RCC):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →